Loading organizations...
§ Private Profile · 11150 S Wilcrest Dr #100, Houston, TX 77099, USA
Telehealth platform providing direct-to-consumer diagnostic testing and treatment services for sexual health and wellness.
Based in Houston, Texas, Analyte Health is a digital health company providing a national telehealth platform for direct-to-consumer diagnostic testing, virtual consultations, and prescription fulfillment. The organization operates a comprehensive physician network covering all fifty states and has processed over two million diagnostic test results for millions of individual patients. Operating with a workforce of approximately seventy-five employees, the company manages a portfolio of consumer wellness brands including STDcheck, HealthLabs, and PaternityLab. The enterprise has raised over thirty million dollars in total venture capital funding from notable investors including Bessemer Venture Partners and Mohr Davidow Ventures. Originally founded in 2009 by Dan Hermann, the business later expanded its integrated platforms under the leadership of current chief executive officer Fiyyaz Pirani. In August 2025, the healthcare enterprise was acquired by the private equity firm Brightstar Capital Partners.
Analyte Health has raised $55.0M across 4 funding rounds.
Analyte Health has raised $55.0M in total across 4 funding rounds.
Analyte Health is a technology-driven digital health company that provides direct-to-consumer diagnostics, telemedicine, and treatment services, empowering patients with convenient, confidential, and affordable access to healthcare information.[1][2][4][5] It combines a national network of over 5,600 patient service diagnostic centers, at-home collection kits, online digital platforms, and telehealth capabilities to deliver lab testing, virtual consultations, and prescription fulfillment, primarily in wellness, sexual health, and hormonal therapies, having served millions of patients and issued over 2.2 million test results since inception.[1][2][3][4][5] The company targets consumers seeking discreet alternatives to traditional healthcare, partnering with pharmaceutical firms, telehealth providers, and labs to promote clinical compliance and health awareness, while maintaining affordability through negotiated rates and technology efficiencies.[1][2][3]
Founded by Fiyyaz Pirani, who serves as CEO, Analyte Health (formerly Analyte Media) emerged around 12 years ago to address barriers in accessing affordable online healthcare, particularly for those uncomfortable with in-person visits.[3][5] Pirani launched the company to deliver easy, accessible telemedicine and diagnostic services, starting with digital consultations and remote counseling in the medical sector.[2][3] Early traction came from building a national footprint, including patient service centers and online assets, helping thousands weekly and scaling to over 2.2 million test results; a pivotal moment was its 2018 STI testing survey highlighting public health gaps.[1][2][3] In a recent milestone, private equity firm Brightstar Capital Partners acquired the company, with Pirani retaining a significant ownership stake and continuing as CEO to fuel expansion.[5][6]
Analyte Health rides the direct-to-consumer (DTC) telehealth and digital diagnostics trend, capitalizing on rising consumer demand for convenient, private health management amid seismic shifts away from traditional channels.[5][6] Timing aligns with post-pandemic acceleration in virtual care, where consumers prioritize control over logistics, supported by market forces like expanding digital health infrastructure (e.g., sensors, platforms) and wellness focus.[2][6] It influences the ecosystem by enabling pharma/telehealth partnerships, publishing awareness data (e.g., STI surveys), and scaling via PE investment, positioning as a leader in consumer-driven healthcare revolution.[1][2][5]
Analyte Health is primed for accelerated growth under Brightstar's backing, expanding DTC offerings in high-demand areas like hormonal therapies and wellness while leveraging its scalable tech and brand portfolio.[5][6] Trends such as AI-enhanced diagnostics, broader telehealth adoption, and consumer health empowerment will shape its path, potentially solidifying it as a dominant DTC platform amid evolving regulations and personalization demands. Its influence may evolve from service provider to ecosystem enabler, further bridging tech and patient-centric care for sustained momentum in digital health.[5][6]
Analyte Health has raised $55.0M in total across 4 funding rounds.
Analyte Health's investors include DFJ, Pritzker Group.
Analyte Health has raised $55.0M across 4 funding rounds. Most recently, it raised $3.0M Other Equity in September 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 20, 2017 | $3M Venture Round | — | — | Announced |
| Sep 1, 2017 | $27M Series U | — | DFJ, Pritzker Group | Announced |
| Jul 1, 2012 | $22M Series U | — | DFJ, Pritzker Group | Announced |
| Oct 1, 2008 | $3M Seed | — | DFJ, Pritzker Group | Announced |